Dataset from Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at
least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte
colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at
least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1
Diabetes (T1D).

The primary objective of the study will be to determine the safety and ability of low dose
ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D
patients demonstrating residual beta cell function.